Skip Nav Destination
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
How I treat mixed-phenotype acute leukemia
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
Issue Archive
April 16 2015
In this Issue
Table of Contents
INSIDE BLOOD COMMENTARIES
PERSPECTIVES
BLOOD FORUM
BLOOD SPOTLIGHT
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
Clinical Trials & Observations
HOW I TREAT
How I treat mixed-phenotype acute leukemia
Clinical Trials & Observations
CLINICAL TRIALS AND OBSERVATIONS
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
CME
Clinical Trials & Observations
Nathalie Dhédin,on behalf of the GRAALL group,Anne Huynh,on behalf of the GRAALL group,Sébastien Maury,on behalf of the GRAALL group,Reza Tabrizi,on behalf of the GRAALL group,Kheira Beldjord,on behalf of the GRAALL group,Vahid Asnafi,on behalf of the GRAALL group,Xavier Thomas,on behalf of the GRAALL group,Patrice Chevallier,on behalf of the GRAALL group,Stéphanie Nguyen,on behalf of the GRAALL group,Valérie Coiteux,on behalf of the GRAALL group,Jean-Henri Bourhis,on behalf of the GRAALL group,Yosr Hichri,on behalf of the GRAALL group,Martine Escoffre-Barbe,on behalf of the GRAALL group,Oumedaly Reman,on behalf of the GRAALL group,Carlos Graux,on behalf of the GRAALL group,Yves Chalandon,on behalf of the GRAALL group,Didier Blaise,on behalf of the GRAALL group,Urs Schanz,on behalf of the GRAALL group,Véronique Lhéritier,on behalf of the GRAALL group,Jean-Yves Cahn,on behalf of the GRAALL group,Hervé Dombret,on behalf of the GRAALL group,Norbert Ifrah,on behalf of the GRAALL group
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib
Clinical Trials & Observations
John C. Byrd,Richard R. Furman,Steven E. Coutre,Jan A. Burger,Kristie A. Blum,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Yun Shaw,Elizabeth Bilotti,Cathy Zhou,Danelle F. James,Susan O'Brien
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation
Lapo Alinari,Kiran V. Mahasenan,Fengting Yan,Vrajesh Karkhanis,Ji-Hyun Chung,Emily M. Smith,Carl Quinion,Porsha L. Smith,Lisa Kim,John T. Patton,Rosa Lapalombella,Bo Yu,Yun Wu,Satavisha Roy,Alessandra De Leo,Stefano Pileri,Claudio Agostinelli,Leona Ayers,James E. Bradner,Selina Chen-Kiang,Olivier Elemento,Tasneem Motiwala,Sarmila Majumder,John C. Byrd,Samson Jacob,Said Sif,Chenglong Li,Robert A. Baiocchi
MYELOID NEOPLASIA
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
TRANSPLANTATION
Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma
Clinical Trials & Observations
Brief Report
Craig S. Sauter,Matthew J. Matasar,Jessica Meikle,Heiko Schoder,Gary A. Ulaner,Jocelyn C. Migliacci,Patrick Hilden,Sean M. Devlin,Andrew D. Zelenetz,Craig H. Moskowitz
BLOOD WORK
ERRATA
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
Myeloperoxidase cytochemical reaction performed on a bone marrow aspirate smear from a patient with mixed phenotype acute leukemia reveals a differential staining pattern in the 2 blast populations. See the article by Wolach and Stone on page 2477.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals